{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T11:45:22Z","timestamp":1790163922236,"version":"4.1.0"},"reference-count":242,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T00:00:00Z","timestamp":1609891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T00:00:00Z","timestamp":1609891200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["2P30CA008748-48"],"award-info":[{"award-number":["2P30CA008748-48"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Mature B cell neoplasms, previously indolent non-Hodgkin lymphomas (iNHLs), are a heterogeneous group of malignancies sharing similar disease courses and treatment paradigms. Most patients with iNHL have an excellent prognosis, and in many, treatment can be deferred for years. However, some patients will have an accelerated course and may experience transformation into aggressive lymphomas. In this review, we focus on management concepts shared across iNHLs, as well as histology-specific strategies. We address open questions in the field, including the influence of genomics and molecular pathway alterations on treatment decisions. In addition, we review the management of uncommon clinical entities including nodular lymphocyte-predominant Hodgkin lymphoma, hairy cell leukemia, splenic lymphoma and primary lymphoma of extranodal sites. Finally, we include a perspective on novel targeted therapies, antibodies, antibody\u2013drug conjugates, bispecific T cell engagers and chimeric antigen receptor T cell therapy.<\/jats:p>","DOI":"10.1186\/s13045-020-01018-6","type":"journal-article","created":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T19:04:06Z","timestamp":1609959846000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["How we treat mature B-cell neoplasms (indolent B-cell lymphomas)"],"prefix":"10.1186","volume":"14","author":[{"given":"Melissa","family":"Lumish","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Falchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon S.","family":"Imber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Scordo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gottfried","family":"von Keudell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7883-289X","authenticated-orcid":false,"given":"Erel","family":"Joffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,6]]},"reference":[{"key":"1018_CR1","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1111\/bjh.15805","volume":"185","author":"L Magnano","year":"2019","unstructured":"Magnano L, et al. Life expectancy of follicular lymphoma patients in complete response at 30 months is similar to that of the Spanish general population. Br J Haematol. 2019;185:480\u201391.","journal-title":"Br J Haematol"},{"key":"1018_CR2","doi-asserted-by":"publisher","first-page":"3989","DOI":"10.1182\/blood.V126.23.3989.3989","volume":"126","author":"C Tarella","year":"2015","unstructured":"Tarella C, et al. Life expectancy in follicular lymphoma is mainly determined by response to first LINE treatment: a long-term survey on 597 patients. Blood. 2015;126:3989\u20133989.","journal-title":"Blood"},{"key":"1018_CR3","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1200\/JCO.18.00400","volume":"37","author":"C Sarkozy","year":"2019","unstructured":"Sarkozy C, et al. Cause of death in follicular lymphoma in the first decade of the rituximab era: a pooled analysis of French and US cohorts. J Clin Oncol. 2019;37:144\u201352.","journal-title":"J Clin Oncol"},{"key":"1018_CR4","doi-asserted-by":"publisher","first-page":"339","DOI":"10.3324\/haematol.2012.081885","volume":"99","author":"SAM van de Schans","year":"2014","unstructured":"van de Schans SAM, van Steenbergen LN, Coebergh JWW, Janssen-Heijnen MLG, van Spronsen DJ. Actual prognosis during follow-up of survivors of B-cell non-Hodgkin lymphoma in the Netherlands. Haematologica. 2014;99:339\u201345.","journal-title":"Haematologica"},{"key":"1018_CR5","unstructured":"Howlader N, et al. Cancer statistics review, 1975\u20132017\u2014SEER statistics. SEER cancer statistics review, 1975\u20132017, National Cancer Institute, Bethesda, MD. https:\/\/seer.cancer.gov\/csr\/1975_2017\/ (2019)."},{"key":"1018_CR6","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1182\/blood.V118.21.1593.1593","volume":"118","author":"C Lobetti-Bodoni","year":"2011","unstructured":"Lobetti-Bodoni C, et al. The importance of age in prognosis of follicular lymphoma: clinical features and life expectancy of patients younger than 40 years. Blood. 2011;118:1593\u20131593.","journal-title":"Blood"},{"key":"1018_CR7","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41408-020-00340-z","volume":"10","author":"CL Batlevi","year":"2020","unstructured":"Batlevi CL, et al. Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups. Blood Cancer J. 2020a;10:74.","journal-title":"Blood Cancer J"},{"key":"1018_CR8","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.1200\/JCO.2012.48.3990","volume":"31","author":"BK Link","year":"2013","unstructured":"Link BK, et al. Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: A report from the university of Iowa\/mayo clinic specialized program of research excellence molecular epidemiology resource. J Clin Oncol. 2013;31:3272\u20138.","journal-title":"J Clin Oncol"},{"key":"1018_CR9","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1007\/s00277-020-04025-2","volume":"99","author":"C Sortais","year":"2020","unstructured":"Sortais C, et al. Progression of disease within 2 years (POD24) is a clinically relevant endpoint to identify high-risk follicular lymphoma patients in real life. Ann Hematol. 2020;99:1595\u2013604.","journal-title":"Ann Hematol"},{"key":"1018_CR10","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1200\/JCO.2004.10.086","volume":"22","author":"R Advani","year":"2004","unstructured":"Advani R, Rosenberg SA, Horning SJ. Stage I and II follicular non-Hodgkin\u2019s lymphoma: long-term follow-up of no initial therapy. J Clin Oncol Off J Am Soc Clin Oncol. 2004;22:1454\u20139.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"1018_CR11","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1200\/JCO.1997.15.3.1110","volume":"15","author":"P Brice","year":"1997","unstructured":"Brice P, et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d\u2019Etude des Lymphomes Folliculaires. Groupe d\u2019Etude des Lymphomes de l\u2019Adulte. J Clin Oncol. 1997;15:1110\u20137.","journal-title":"J Clin Oncol"},{"key":"1018_CR12","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/S0140-6736(03)14110-4","volume":"362","author":"KM Ardeshna","year":"2003","unstructured":"Ardeshna KM, et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet. 2003;362:516\u201322.","journal-title":"Lancet"},{"key":"1018_CR13","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1111\/bjh.16011","volume":"186","author":"C Casulo","year":"2019","unstructured":"Casulo C. How I manage patients with follicular lymphoma. Br J Haematol. 2019;186:513\u201323.","journal-title":"Br J Haematol"},{"key":"1018_CR14","doi-asserted-by":"publisher","first-page":"2904","DOI":"10.1200\/JCO.2018.79.3075","volume":"36","author":"JC Yang","year":"2018","unstructured":"Yang JC, Yahalom J. Early-stage follicular lymphoma: what is the preferred treatment strategy? J Clin Oncol. 2018;36:2904\u20136.","journal-title":"J Clin Oncol"},{"key":"1018_CR15","doi-asserted-by":"publisher","first-page":"e1236","DOI":"10.1634\/theoncologist.2019-0138","volume":"24","author":"MJ Matasar","year":"2019","unstructured":"Matasar MJ, et al. Follicular lymphoma: recent and emerging therapies, treatment strategies, and remaining unmet needs. Oncologist. 2019;24:e1236\u201350.","journal-title":"Oncologist"},{"key":"1018_CR16","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.hoc.2019.03.002","volume":"33","author":"B Diamond","year":"2019","unstructured":"Diamond B, Kumar A. Mantle cell lymphoma: current and emerging treatment strategies and unanswered questions. Hematol Oncol Clin North Am. 2019;33:613\u201326.","journal-title":"Hematol Oncol Clin North Am"},{"key":"1018_CR17","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1007\/s11864-014-0286-4","volume":"15","author":"J Yahalom","year":"2014","unstructured":"Yahalom J. Radiotherapy of follicular lymphoma: updated role and new rules. Curr Treat Options Oncol. 2014;15:262\u20138.","journal-title":"Curr Treat Options Oncol"},{"key":"1018_CR18","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s11912-018-0687-9","volume":"20","author":"S Ayyappan","year":"2018","unstructured":"Ayyappan S, William BM. Marginal zone lymphoma: clinicopathologic variations and approaches to therapy. Curr Oncol Rep. 2018;20:33.","journal-title":"Curr Oncol Rep"},{"key":"1018_CR19","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1200\/JCO.19.02314","volume":"38","author":"SP Treon","year":"2020","unstructured":"Treon SP, et al. Genomic landscape of Waldenstr\u00f6m macroglobulinemia and its impact on treatment strategies. J Clin Oncol. 2020;38:1198\u2013208.","journal-title":"J Clin Oncol"},{"key":"1018_CR20","doi-asserted-by":"publisher","first-page":"2804","DOI":"10.1182\/bloodadvances.2019000458","volume":"3","author":"JWD Tobin","year":"2019","unstructured":"Tobin JWD, et al. Outcomes of stage I\/II follicular lymphoma in the PET era: an international study from the Australian Lymphoma Alliance. Blood Adv. 2019;3:2804\u201311.","journal-title":"Blood Adv"},{"key":"1018_CR21","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1182\/blood-2008-07-168682","volume":"113","author":"T Katzenberger","year":"2009","unstructured":"Katzenberger T, et al. A distinctive subtype of t(14;18)-negative nodal follicular non-Hodgkin lymphoma characterized by a predominantly diffuse growth pattern and deletions in the chromosomal region 1p36. Blood. 2009;113:1053\u201361.","journal-title":"Blood"},{"key":"1018_CR22","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1182\/blood.2019000560","volume":"135","author":"AM Staiger","year":"2020","unstructured":"Staiger AM, et al. Localized- and advanced-stage follicular lymphomas differ in their gene expression profiles. Blood. 2020;135:181\u201390.","journal-title":"Blood"},{"key":"1018_CR23","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1182\/blood-2009-01-198580","volume":"114","author":"E Leich","year":"2009","unstructured":"Leich E, et al. Follicular lymphomas with and without translocation t(14;18) differ in gene expression profiles and genetic alterations. Blood. 2009;114:826\u201334.","journal-title":"Blood"},{"key":"1018_CR24","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1038\/leu.2015.330","volume":"30","author":"E Leich","year":"2016","unstructured":"Leich E, et al. Similar clinical features in follicular lymphomas with and without breaks in the BCL2 locus. Leukemia. 2016;30:854\u201360.","journal-title":"Leukemia"},{"key":"1018_CR25","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1093\/oxfordjournals.annonc.a010720","volume":"7","author":"P Soubeyran","year":"1996","unstructured":"Soubeyran P, et al. Is there any place for a wait-and-see policy in stage I0 follicular lymphoma? A study of 43 consecutive patients in a single center. Ann Oncol. 1996;7:713\u20138.","journal-title":"Ann Oncol"},{"key":"1018_CR26","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1200\/JCO.2010.32.9193","volume":"29","author":"AI Schmatz","year":"2011","unstructured":"Schmatz AI, et al. Primary follicular lymphoma of the duodenum is a distinct mucosal\/submucosal variant of follicular lymphoma: a retrospective study of 63 cases. J Clin Oncol. 2011;29:1445\u201351.","journal-title":"J Clin Oncol"},{"key":"1018_CR27","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s00384-011-1309-2","volume":"27","author":"C Beaton","year":"2012","unstructured":"Beaton C, Davies M, Beynon J. The management of primary small bowel and colon lymphoma-a review. Int J Colorectal Dis. 2012;27:555\u201363.","journal-title":"Int J Colorectal Dis"},{"key":"1018_CR28","doi-asserted-by":"publisher","first-page":"2857","DOI":"10.1200\/JCO.2014.60.4363","volume":"33","author":"DA Eichenauer","year":"2015","unstructured":"Eichenauer DA, et al. Long-term course of patients with stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin study group. J Clin Oncol. 2015;33:2857\u201362.","journal-title":"J Clin Oncol"},{"key":"1018_CR29","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.radonc.2011.05.013","volume":"100","author":"L Lowry","year":"2011","unstructured":"Lowry L, et al. Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial. Radiother Oncol. 2011;100:86\u201392.","journal-title":"Radiother Oncol"},{"key":"1018_CR30","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1016\/S0360-3016(01)01747-3","volume":"51","author":"RB Wilder","year":"2001","unstructured":"Wilder RB, et al. Long-term results with radiotherapy for stage I-II follicular lymphomas. Int J Radiat Oncol. 2001;51:1219\u201327.","journal-title":"Int J Radiat Oncol"},{"key":"1018_CR31","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1182\/blood-2018-04-843540","volume":"133","author":"JL Brady","year":"2019","unstructured":"Brady JL, et al. Definitive radiotherapy for localized follicular lymphoma staged by 18F-FDG PET-CT: a collaborative study by ILROG. Blood. 2019a;133:237\u201345.","journal-title":"Blood"},{"key":"1018_CR32","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1182\/blood.2019004588","volume":"136","author":"A Lo","year":"2020","unstructured":"Lo A, et al. Long-term outcomes for patients with limited-stage follicular lymphoma: update of a population-based study. Blood. 2020;136:1006\u201310.","journal-title":"Blood"},{"key":"1018_CR33","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1093\/annonc\/mdx025","volume":"28","author":"S Teckie","year":"2017","unstructured":"Teckie S, et al. Long-term outcome of 487 patients with early-stage extra-nodal marginal zone lymphoma. Ann Oncol. 2017;28:1064\u20139.","journal-title":"Ann Oncol"},{"key":"1018_CR34","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1080\/10428194.2016.1204653","volume":"58","author":"DA Barzenje","year":"2017","unstructured":"Barzenje DA, et al. Long-term outcome for patients with early stage marginal zone lymphoma and mantle cell lymphoma. Leuk Lymphoma. 2017;58:623\u201332.","journal-title":"Leuk Lymphoma"},{"key":"1018_CR35","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1200\/JCO.2008.18.1495","volume":"27","author":"JW Friedberg","year":"2009","unstructured":"Friedberg JW, et al. Follicular lymphoma in the united states: first report of the national lymphocare study. J Clin Oncol. 2009;27:1202\u20138.","journal-title":"J Clin Oncol"},{"key":"1018_CR36","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/j.ijrobp.2015.12.019","volume":"94","author":"M Ruella","year":"2016","unstructured":"Ruella M, et al. Addition of rituximab to involved-field radiation therapy prolongs progression-free survival in stage I\u2013II follicular lymphoma: results of a multicenter study. Int J Radiat Oncol Biol Phys. 2016;94:783\u201391.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1018_CR37","doi-asserted-by":"publisher","first-page":"3368","DOI":"10.1200\/JCO.2011.40.6546","volume":"30","author":"JW Friedberg","year":"2012","unstructured":"Friedberg JW, et al. Effectiveness of first-line management strategies for stage I follicular lymphoma: analysis of the National Lymphocare Study. J Clin Oncol. 2012;30:3368\u201375.","journal-title":"J Clin Oncol"},{"key":"1018_CR38","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ijrobp.2014.01.006","volume":"89","author":"T Illidge","year":"2014","unstructured":"Illidge T, et al. Modern radiation therapy for nodal non-hodgkin lymphoma\u2014target definition and dose guidelines from the international lymphoma radiation oncology group. Int J Radiat Oncol. 2014;89:49\u201358.","journal-title":"Int J Radiat Oncol"},{"key":"1018_CR39","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ijrobp.2015.01.009","volume":"92","author":"J Yahalom","year":"2015","unstructured":"Yahalom J, et al. Modern radiation therapy for extranodal lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys. 2015;92:11\u201331.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1018_CR40","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.semradonc.2007.02.006","volume":"17","author":"RW Tsang","year":"2007","unstructured":"Tsang RW, Gospodarowicz MK. Low-grade non-hodgkin lymphomas. Semin Radiat Oncol. 2007;17:198\u2013205.","journal-title":"Semin Radiat Oncol"},{"key":"1018_CR41","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/j.ijrobp.2005.08.010","volume":"64","author":"BA Guadagnolo","year":"2006","unstructured":"Guadagnolo BA, et al. Long-term outcome and mortality trends in early-stage, Grade 1\u20132 follicular lymphoma treated with radiation therapy. Int J Radiat Oncol. 2006;64:928\u201334.","journal-title":"Int J Radiat Oncol"},{"key":"1018_CR42","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1023\/A:1008328226599","volume":"10","author":"WY Au","year":"1999","unstructured":"Au WY, et al. Incidence of second neoplasms in patients with MALT lymphoma: no increase in risk above the background population. Ann Oncol Off J Eur Soc Med Oncol. 1999;10:317\u201321.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"1018_CR43","doi-asserted-by":"publisher","first-page":"3815","DOI":"10.1002\/cncr.25226","volume":"116","author":"JS Goda","year":"2010","unstructured":"Goda JS, et al. Long-term outcome in localized extranodal mucosa-associated lymphoid tissue lymphomas treated with radiotherapy. Cancer. 2010;116:3815\u201324.","journal-title":"Cancer"},{"key":"1018_CR44","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1002\/1097-0142(19801101)46:9<2093::AID-CNCR2820460931>3.0.CO;2-4","volume":"46","author":"JG Krikorian","year":"1980","unstructured":"Krikorian JG, Portlock CS, Cooney P, Rosenberg SA. Spontaneous regression of non-Hodgkin\u2019s lymphoma: a report of nine cases. Cancer. 1980;46:2093\u20139.","journal-title":"Cancer"},{"key":"1018_CR45","doi-asserted-by":"publisher","first-page":"3843","DOI":"10.1002\/cncr.25149","volume":"116","author":"TJ Pugh","year":"2010","unstructured":"Pugh TJ, Ballonoff A, Newman F, Rabinovitch R. Improved survival in patients with early stage low-grade follicular lymphoma treated with radiation. Cancer. 2010;116:3843\u201351.","journal-title":"Cancer"},{"key":"1018_CR46","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/1756-8722-6-45","volume":"6","author":"A-SAS Michallet","year":"2013","unstructured":"Michallet A-SAS, et al. Early stage follicular lymphoma: what is the clinical impact of the first-line treatment strategy? J Hematol Oncol. 2013;6:45.","journal-title":"J Hematol Oncol"},{"key":"1018_CR47","doi-asserted-by":"publisher","first-page":"e0131158","DOI":"10.1371\/journal.pone.0131158","volume":"10","author":"DA Barzenje","year":"2015","unstructured":"Barzenje DA, et al. Radiotherapy compared to other strategies in the treatment of stage I\/II follicular lymphoma: a study of 404 patients with a median follow-up of 15 years. PLoS ONE. 2015;10:e0131158.","journal-title":"PLoS ONE"},{"key":"1018_CR48","doi-asserted-by":"publisher","first-page":"2699","DOI":"10.1002\/1097-0142(19821215)50:12<2699::AID-CNCR2820501202>3.0.CO;2-A","volume":"50","author":"T Anderson","year":"1982","unstructured":"Anderson T, et al. Malignant lymphoma. 1. The histology and staging of 473 patients at the National Cancer Institute. Cancer. 1982;50:2699\u2013707.","journal-title":"Cancer"},{"key":"1018_CR49","doi-asserted-by":"publisher","first-page":"278","DOI":"10.5009\/gnl17217","volume":"12","author":"SI Choi","year":"2018","unstructured":"Choi SI, et al. Prevalence and implications of bone marrow involvement in patients with gastric mucosa-associated lymphoid tissue lymphoma. Gut Liver. 2018;12:278\u201387.","journal-title":"Gut Liver"},{"key":"1018_CR50","first-page":"933","volume-title":"Chapter 13\u2014hematopoietic lesions\u2014diagnostic surgical pathology of the head and neck","author":"MS Brandwein-Gensler","year":"2009","unstructured":"Brandwein-Gensler MS, Mahadevia P, Gnepp DR. Chapter 13\u2014hematopoietic lesions\u2014diagnostic surgical pathology of the head and neck. 2nd ed. Philadelphia: W.B. Saunders; 2009. p. 933\u201374.","edition":"2"},{"key":"1018_CR51","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1111\/j.1365-2141.2006.06437.x","volume":"136","author":"L Arcaini","year":"2007","unstructured":"Arcaini L, et al. Primary nodal marginal zone B-cell lymphoma: clinical features and prognostic assessment of a rare disease. Br J Haematol. 2007;136:301\u20134.","journal-title":"Br J Haematol"},{"key":"1018_CR52","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1093\/ajcp\/92.2.228","volume":"92","author":"A Carbone","year":"1989","unstructured":"Carbone A, et al. Monocytoid B-cell lymphoma with bone marrow and peripheral blood involvement at presentation. Am J Clin Pathol. 1989;92:228\u201336.","journal-title":"Am J Clin Pathol"},{"key":"1018_CR53","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1200\/JCO.1998.16.8.2780","volume":"16","author":"JO Armitage","year":"1998","unstructured":"Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin\u2019s lymphomas: clinical features of the major histologic subtypes. J Clin Oncol. 1998;16:2780\u201395.","journal-title":"J Clin Oncol"},{"key":"1018_CR54","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1046\/j.1365-2141.1998.00684.x","volume":"101","author":"PL Cohen","year":"1998","unstructured":"Cohen PL, Kurtin PJ, Donovan KA, Hanson CA. Bone marrow and peripheral blood involvement in mantle cell lymphoma. Br J Haematol. 1998;101:302\u201310.","journal-title":"Br J Haematol"},{"key":"1018_CR55","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3109\/10428199609067588","volume":"21","author":"S Pittaluga","year":"1996","unstructured":"Pittaluga S, et al. Prognostic significance of bone marrow trephine and peripheral blood smears in 55 patients with mantle cell lymphoma. Leuk Lymphoma. 1996;21:115\u201325.","journal-title":"Leuk Lymphoma"},{"key":"1018_CR56","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1093\/ajcp\/108.3.302","volume":"108","author":"MA Vasef","year":"1997","unstructured":"Vasef MA, Medeiros LJ, Koo C, McCourty A, Brynes RK. Cyclin D1 immunohistochemical staining is useful in distinguishing mantle cell lymphoma from other low-grade B-cell neoplasms in bone marrow. Am J Clin Pathol. 1997;108:302\u20137.","journal-title":"Am J Clin Pathol"},{"key":"1018_CR57","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1093\/ajcp\/106.2.196","volume":"106","author":"J Wasman","year":"1996","unstructured":"Wasman J, Rosenthal NS, Farhi DC. Mantle cell lymphoma. Morphologic findings in bone marrow involvement. Am J Clin Pathol. 1996;106:196\u2013200.","journal-title":"Am J Clin Pathol"},{"key":"1018_CR58","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1111\/bjh.16125","volume":"188","author":"A Pulsoni","year":"2020","unstructured":"Pulsoni A, et al. Minimal residual disease monitoring in early stage follicular lymphoma can predict prognosis and drive treatment with rituximab after radiotherapy. Br J Haematol. 2020;188:249\u201358.","journal-title":"Br J Haematol"},{"key":"1018_CR59","doi-asserted-by":"publisher","first-page":"2966","DOI":"10.1182\/blood.V128.22.2966.2966","volume":"128","author":"D Kato","year":"2016","unstructured":"Kato D, et al. The clinical impact of minimal bone marrow involvement on the outcome of patients with follicular lymphoma. Blood. 2016;128:2966\u20132966.","journal-title":"Blood"},{"key":"1018_CR60","doi-asserted-by":"publisher","first-page":"4555","DOI":"10.1200\/JCO.2008.21.3991","volume":"27","author":"M Federico","year":"2009","unstructured":"Federico M, et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol. 2009;27:4555\u201362.","journal-title":"J Clin Oncol"},{"key":"1018_CR61","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.ijrobp.2019.03.004","volume":"104","author":"MS Binkley","year":"2019","unstructured":"Binkley MS, et al. Salvage treatment and survival for relapsed follicular lymphoma following primary radiation therapy: a collaborative study on behalf of ILROG. Int J Radiat Oncol Biol Phys. 2019;104:522\u20139.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1018_CR62","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1080\/10428194.2019.1644333","volume":"61","author":"JR Gunther","year":"2020","unstructured":"Gunther JR, et al. Radiation therapy for salivary gland MALT lymphoma: ultra-low dose treatment achieves encouraging early outcomes and spares salivary function. Leuk Lymphoma. 2020;61:171\u20135.","journal-title":"Leuk Lymphoma"},{"key":"1018_CR63","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1002\/hed.24717","volume":"39","author":"CC Pinnix","year":"2017","unstructured":"Pinnix CC, et al. Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma. Head Neck. 2017;39:1095\u2013100.","journal-title":"Head Neck"},{"key":"1018_CR64","doi-asserted-by":"publisher","first-page":"2918","DOI":"10.1200\/JCO.2018.77.9892","volume":"36","author":"M MacManus","year":"2018","unstructured":"MacManus M, et al. Randomized trial of systemic therapy after involved-field radiotherapy in patients with early-stage follicular lymphoma: TROG 99.03. J Clin Oncol. 2018;36:2918\u201325.","journal-title":"J Clin Oncol"},{"key":"1018_CR65","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1200\/JCO.2003.07.111","volume":"21","author":"JF Seymour","year":"2003","unstructured":"Seymour JF, et al. Long-term follow-up of a prospective study of combined modality therapy for stage I\u2013II indolent non-Hodgkin\u2019s lymphoma. J Clin Oncol. 2003;21:2115\u201322.","journal-title":"J Clin Oncol"},{"key":"1018_CR66","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1182\/blood-2018-04-843540","volume":"133","author":"JL Brady","year":"2019","unstructured":"Brady JL, et al. Definitive radiotherapy for localized follicular lymphoma staged by18F-FDG PET-CT: a collaborative study by ILROG. Blood. 2019b;133:237\u201345.","journal-title":"Blood"},{"key":"1018_CR67","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1056\/NEJM198412063112303","volume":"311","author":"SJ Horning","year":"1984","unstructured":"Horning SJ, Rosenberg SA. The natural history of initially untreated low-grade non-Hodgkin\u2019s lymphomas. N Engl J Med. 1984;311:1471\u20135.","journal-title":"N Engl J Med"},{"key":"1018_CR68","first-page":"11","volume":"25","author":"RC Young","year":"1988","unstructured":"Young RC, et al. The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment. Semin Hematol. 1988;25:11\u20136.","journal-title":"Semin Hematol"},{"key":"1018_CR69","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1080\/1042819021000016050","volume":"43","author":"F Morabito","year":"2002","unstructured":"Morabito F, et al. Prospective study of indolent non-follicular non-Hodgkin\u2019s lymphoma: validation of Gruppo Italiano Per Lo Studio Dei Linfomi (GISL) prognostic criteria for watch and wait policy. Leuk Lymphoma. 2002;43:1933\u20138.","journal-title":"Leuk Lymphoma"},{"key":"1018_CR70","doi-asserted-by":"publisher","first-page":"2996","DOI":"10.1002\/cncr.30137","volume":"122","author":"SK Barta","year":"2016","unstructured":"Barta SK, et al. Randomized phase 3 study in low-grade lymphoma comparing maintenance anti-CD20 antibody with observation after induction therapy: a trial of the ECOG-ACRIN cancer research group (E1496). Cancer. 2016;122:2996\u20133004.","journal-title":"Cancer"},{"key":"1018_CR71","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1182\/blood-2018-10-877761","volume":"133","author":"S Borchmann","year":"2019","unstructured":"Borchmann S, et al. Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma. Blood. 2019;133:2121\u20139.","journal-title":"Blood"},{"key":"1018_CR72","doi-asserted-by":"publisher","first-page":"e163","DOI":"10.3324\/haematol.2018.201350","volume":"104","author":"A Kumar","year":"2019","unstructured":"Kumar A, et al. Clinical presentation determines selection of patients for initial observation in mantle cell lymphoma. Haematologica. 2019;104:e163\u20136.","journal-title":"Haematologica"},{"key":"1018_CR73","doi-asserted-by":"crossref","unstructured":"Kyle RA, et al. Prognostic markers and criteria to initiate therapy in Waldenstrom\u2019s macroglobulinemia: Consensus panel recommendations from the Second International Workshop on Waldenstrom\u2019s Macroglobulinemia. In: Seminars in oncology. vol. 30. W.B. Saunders; 2003. p. 116\u201320.","DOI":"10.1053\/sonc.2003.50038"},{"key":"1018_CR74","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1111\/imj.14268","volume":"49","author":"CY Cheah","year":"2019","unstructured":"Cheah CY, Opat S, Trotman J, Marlton P. Front-line management of indolent non-Hodgkin lymphoma in Australia. Part 2: mantle cell lymphoma and marginal zone lymphoma. Intern Med J. 2019;49:1070\u201380.","journal-title":"Intern Med J"},{"key":"1018_CR75","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/S1470-2045(14)70027-0","volume":"15","author":"KM Ardeshna","year":"2014","unstructured":"Ardeshna KM, et al. Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: An open-label randomised phase 3 trial. Lancet Oncol. 2014;15:424\u201335.","journal-title":"Lancet Oncol"},{"key":"1018_CR76","doi-asserted-by":"publisher","first-page":"3096","DOI":"10.1200\/JCO.2014.56.5853","volume":"32","author":"BS Kahl","year":"2014","unstructured":"Kahl BS, et al. Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: eastern cooperative oncology group protocol E4402. J Clin Oncol. 2014;32:3096\u2013102.","journal-title":"J Clin Oncol"},{"key":"1018_CR77","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1111\/bjh.14007","volume":"173","author":"ME Williams","year":"2016","unstructured":"Williams ME, et al. Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402. Br J Haematol. 2016;173:867\u201375.","journal-title":"Br J Haematol"},{"key":"1018_CR78","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1093\/jjco\/hyy085","volume":"48","author":"K Miyamoto","year":"2018","unstructured":"Miyamoto K, et al. Phase III study of watchful waiting vs. rituximab as first-line treatment in advanced stage follicular lymphoma with low tumour burden (JCOG1411, FLORA study). Jpn J Clin Oncol. 2018;48:777\u201380.","journal-title":"Jpn J Clin Oncol"},{"key":"1018_CR79","doi-asserted-by":"publisher","first-page":"4480","DOI":"10.1200\/JCO.2010.28.4786","volume":"28","author":"G Martinelli","year":"2010","unstructured":"Martinelli G, et al. Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35\/98. J Clin Oncol. 2010;28:4480\u20134.","journal-title":"J Clin Oncol"},{"key":"1018_CR80","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1182\/blood-2006-01-013367","volume":"108","author":"C Buske","year":"2006","unstructured":"Buske C, et al. The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome. Blood. 2006;108:1504\u20138.","journal-title":"Blood"},{"key":"1018_CR81","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1093\/annonc\/mds429","volume":"24","author":"AK Nooka","year":"2013","unstructured":"Nooka AK, et al. Examination of the follicular lymphoma international prognostic index (FLIPI) in the National LymphoCare study (NLCS): a prospective US patient cohort treated predominantly in community practices. Ann Oncol Off J Eur Soc Med Oncol. 2013;24:441\u20138.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"1018_CR82","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1182\/blood-2017-11-816405","volume":"132","author":"E Bachy","year":"2018","unstructured":"Bachy E, et al. A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy. Blood. 2018;132:49\u201358.","journal-title":"Blood"},{"key":"1018_CR83","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/S1470-2045(15)00169-2","volume":"16","author":"A Pastore","year":"2015","unstructured":"Pastore A, et al. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. Lancet Oncol. 2015;16:1111\u201322.","journal-title":"Lancet Oncol"},{"key":"1018_CR84","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1182\/blood-2019-130208","volume":"134","author":"V Jurinovic","year":"2019","unstructured":"Jurinovic V, et al. Evaluation of the m7-FLIPI in patients with follicular lymphoma treated within the gallium trial: EZH2 mutation status may be a predictive marker for differential efficacy of chemotherapy. Blood. 2019;134:122\u2013122.","journal-title":"Blood"},{"key":"1018_CR85","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1111\/bjh.16159","volume":"188","author":"S Lockmer","year":"2020","unstructured":"Lockmer S, et al. M7-FLIPI is not prognostic in follicular lymphoma patients with first-line rituximab chemo-free therapy. Br J Haematol. 2020;188:259\u201367.","journal-title":"Br J Haematol"},{"key":"1018_CR86","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1111\/bjh.12011","volume":"159","author":"C Montalb\u00e1n","year":"2012","unstructured":"Montalb\u00e1n C, et al. Risk stratification for Splenic Marginal Zone Lymphoma based on haemoglobin concentration, platelet count, high lactate dehydrogenase level and extrahilar lymphadenopathy: development and validation on 593 cases. Br J Haematol. 2012;159:164\u201371.","journal-title":"Br J Haematol"},{"key":"1018_CR87","doi-asserted-by":"publisher","first-page":"4643","DOI":"10.1182\/blood-2005-11-4659","volume":"107","author":"L Arcaini","year":"2006","unstructured":"Arcaini L, et al. Splenic marginal zone lymphoma: A prognostic model for clinical use. Blood. 2006;107:4643\u20139.","journal-title":"Blood"},{"key":"1018_CR88","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1182\/blood-2017-03-771915","volume":"130","author":"C Thieblemont","year":"2017","unstructured":"Thieblemont C, et al. A MALT lymphoma prognostic index. Blood. 2017;130:1409\u201317.","journal-title":"Blood"},{"key":"1018_CR89","doi-asserted-by":"publisher","first-page":"4163","DOI":"10.1182\/blood-2008-08-174961","volume":"113","author":"P Morel","year":"2009","unstructured":"Morel P, et al. International prognostic scoring system for Waldenstr\u00f6m macroglobulinemia. Blood. 2009;113:4163\u201370.","journal-title":"Blood"},{"key":"1018_CR90","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","volume":"104","author":"P Solal-C\u00e9ligny","year":"2004","unstructured":"Solal-C\u00e9ligny P, et al. Follicular lymphoma international prognostic index. Blood. 2004;104:1258\u201365.","journal-title":"Blood"},{"key":"1018_CR91","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","volume":"377","author":"R Marcus","year":"2017","unstructured":"Marcus R, et al. Obinutuzumab for the first-line treatment of follicular lymphoma. N Engl J Med. 2017;377:1331\u201344.","journal-title":"N Engl J Med"},{"key":"1018_CR92","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1200\/JCO.2017.76.8960","volume":"36","author":"W Hiddemann","year":"2018","unstructured":"Hiddemann W, et al. Immunochemotherapy with obinutuzumab or rituximab for previously untreated follicular lymphoma in the GALLIUM study: influence of chemotherapy on efficacy and safety. J Clin Oncol. 2018;36:2395\u2013404.","journal-title":"J Clin Oncol"},{"key":"1018_CR93","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","volume":"377","author":"G Salles","year":"2011","unstructured":"Salles G, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet. 2011;377:42\u201351.","journal-title":"Lancet"},{"key":"1018_CR94","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1200\/JCO.19.01073","volume":"37","author":"E Bachy","year":"2019","unstructured":"Bachy E, et al. Sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma: long-term results of the PRIMA study. J Clin Oncol. 2019;37:2815\u201324.","journal-title":"J Clin Oncol"},{"key":"1018_CR95","doi-asserted-by":"publisher","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","volume":"123","author":"IW Flinn","year":"2014","unstructured":"Flinn IW, et al. Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood. 2014a;123:2944\u201352.","journal-title":"Blood"},{"key":"1018_CR96","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","volume":"381","author":"MJ Rummel","year":"2013","unstructured":"Rummel MJ, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381:1203\u201310.","journal-title":"Lancet"},{"key":"1018_CR97","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1182\/blood.2019001091","volume":"135","author":"F Mir","year":"2020","unstructured":"Mir F, et al. Baseline SUVmax did not predict histological transformation in the phase 3 GALLIUM study in follicular lymphoma. Blood. 2020;135:1214\u20138.","journal-title":"Blood"},{"key":"1018_CR98","doi-asserted-by":"publisher","first-page":"7507","DOI":"10.1200\/JCO.2019.37.15_suppl.7507","volume":"37","author":"EJ Lugtenburg","year":"2019","unstructured":"Lugtenburg EJ, et al. Rituximab maintenance for patients with diffuse large B-cell lymphoma in first complete remission: Results from a randomized HOVON-Nordic Lymphoma Group phase III study. J Clin Oncol. 2019;37:7507\u20137507.","journal-title":"J Clin Oncol"},{"key":"1018_CR99","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1111\/bjh.15720","volume":"184","author":"BT Hill","year":"2019","unstructured":"Hill BT, et al. Maintenance rituximab or observation after frontline treatment with bendamustine-rituximab for follicular lymphoma. Br J Haematol. 2019;184:524\u201335.","journal-title":"Br J Haematol"},{"key":"1018_CR100","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1093\/annonc\/mdi022","volume":"16","author":"SP Treon","year":"2005","unstructured":"Treon SP, et al. Extended rituximab therapy in Waldenstr\u00f6m\u2019s macroglobulinemia. Ann Oncol Off J Eur Soc Med Oncol. 2005;16:132\u20138.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"1018_CR101","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/j.1365-2141.2011.08750.x","volume":"154","author":"SP Treon","year":"2011","unstructured":"Treon SP, et al. Maintenance Rituximab is associated with improved clinical outcome in rituximab na\u00efve patients with Waldenstrom Macroglobulinaemia who respond to a rituximab-containing regimen. Br J Haematol. 2011;154:357\u201362.","journal-title":"Br J Haematol"},{"key":"1018_CR102","doi-asserted-by":"publisher","first-page":"163","DOI":"10.3816\/CLM.2002.n.022","volume":"3","author":"MA Dimopoulos","year":"2002","unstructured":"Dimopoulos MA, et al. Extended rituximab therapy for previously untreated patients with Waldenstr\u00f6m\u2019s macroglobulinemia. Clin Lymphoma. 2002;3:163\u20136.","journal-title":"Clin Lymphoma"},{"key":"1018_CR103","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1200\/JCO.2008.17.1561","volume":"27","author":"H Hochster","year":"2009","unstructured":"Hochster H, et al. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: Results of the randomized phase III ECOG1496 study. J Clin Oncol. 2009;27:1607\u201314.","journal-title":"J Clin Oncol"},{"key":"1018_CR104","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1056\/NEJMoa1805104","volume":"379","author":"F Morschhauser","year":"2018","unstructured":"Morschhauser F, et al. Rituximab plus lenalidomide in advanced untreated follicular lymphoma. N Engl J Med. 2018;379:934\u201347.","journal-title":"N Engl J Med"},{"key":"1018_CR105","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1182\/blood-2019-129422","volume":"134","author":"LJ Nastoupil","year":"2019","unstructured":"Nastoupil LJ, et al. Results of a phase II study of obinutuzumab in combination with lenalidomide in previously untreated, high tumor burden follicular lymphoma (FL). Blood. 2019;134:125\u2013125.","journal-title":"Blood"},{"key":"1018_CR106","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.clml.2020.03.009","volume":"20","author":"BD Cheson","year":"2020","unstructured":"Cheson BD, Morschhauser F, Martin P. Management of adverse events from the combination of rituximab and lenalidomide in the treatment of patients with follicular and low-grade non-Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk. 2020;20:563\u201371.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1018_CR107","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1200\/JCO.2013.53.2069","volume":"32","author":"RH Advani","year":"2014","unstructured":"Advani RH, et al. Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma. J Clin Oncol. 2014;32:912\u20138.","journal-title":"J Clin Oncol"},{"key":"1018_CR108","doi-asserted-by":"publisher","first-page":"2741","DOI":"10.1182\/blood-2002-11-3496","volume":"102","author":"A Conconi","year":"2003","unstructured":"Conconi A, et al. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood. 2003;102:2741\u20135.","journal-title":"Blood"},{"key":"1018_CR109","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1200\/JCO.2016.70.6994","volume":"35","author":"E Zucca","year":"2017","unstructured":"Zucca E, et al. Final results of the IELSG-19 randomized trial of mucosa-associated lymphoid tissue lymphoma: Improved event-free and progression-free survival with rituximab plus chlorambucil versus either chlorambucil or rituximab monotherapy. J Clin Oncol. 2017;35:1905\u201312.","journal-title":"J Clin Oncol"},{"key":"1018_CR110","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1200\/JCO.19.00010","volume":"37","author":"JP Leonard","year":"2019","unstructured":"Leonard JP, et al. AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma. J Clin Oncol. 2019;37:1188\u201399.","journal-title":"J Clin Oncol"},{"key":"1018_CR111","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1056\/NEJMoa1802917","volume":"378","author":"MA Dimopoulos","year":"2018","unstructured":"Dimopoulos MA, et al. Phase 3 trial of ibrutinib plus rituximab in Waldenstr\u00f6m\u2019s macroglobulinemia. N Engl J Med. 2018;378:2399\u2013410.","journal-title":"N Engl J Med"},{"key":"1018_CR112","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","volume":"380","author":"K Fischer","year":"2019","unstructured":"Fischer K, et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med. 2019;380:2225\u201336.","journal-title":"N Engl J Med"},{"key":"1018_CR113","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1111\/bjh.14129","volume":"174","author":"D Chihara","year":"2016","unstructured":"Chihara D, et al. Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial. Br J Haematol. 2016;174:760\u20136.","journal-title":"Br J Haematol"},{"key":"1018_CR114","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1200\/JCO.19.02250","volume":"38","author":"D Chihara","year":"2020","unstructured":"Chihara D, et al. Randomized phase II study of first-line cladribine with concurrent or delayed rituximab in patients with hairy cell leukemia. J Clin Oncol. 2020;38:1527\u20138.","journal-title":"J Clin Oncol"},{"key":"1018_CR115","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1111\/j.1365-2141.2009.07668.x","volume":"145","author":"M Else","year":"2009","unstructured":"Else M, et al. Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis. Br J Haematol. 2009;145:733\u201340.","journal-title":"Br J Haematol"},{"key":"1018_CR116","doi-asserted-by":"publisher","first-page":"2442","DOI":"10.1002\/cncr.21447","volume":"104","author":"M Else","year":"2005","unstructured":"Else M, et al. Long remissions in hairy cell leukemia with purine analogs: a report of 219 patients with a median follow-up of 12.5 years. Cancer. 2005;104:2442\u20138.","journal-title":"Cancer"},{"key":"1018_CR117","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1200\/JCO.2003.05.093","volume":"21","author":"GR Goodman","year":"2003","unstructured":"Goodman GR, Burian C, Koziol JA, Saven A. Extended follow-up of patients with hairy cell leukemia after treatment with cladribine. J Clin Oncol. 2003;21:591\u20136.","journal-title":"J Clin Oncol"},{"key":"1018_CR118","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1182\/blood-2005-01-0173","volume":"106","author":"P Chadha","year":"2005","unstructured":"Chadha P, et al. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA): long-term follow-up of the Northwestern University experience. Blood. 2005;106:241\u20136.","journal-title":"Blood"},{"key":"1018_CR119","doi-asserted-by":"publisher","first-page":"3998","DOI":"10.1182\/blood-2019-124478","volume":"134","author":"JH Park","year":"2019","unstructured":"Park JH, et al. First line chemo-free therapy with the BRAF inhibitor vemurafenib combined with obinutuzumab is effective in patients with Hcl. Blood. 2019;134:3998.","journal-title":"Blood"},{"key":"1018_CR120","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1182\/blood.V126.23.333.333","volume":"126","author":"J Vindi","year":"2015","unstructured":"Vindi J, et al. A clinicogenetic risk model (m7-FLIPI) prospectively identifies one-half of patients with early disease progression of follicular lymphoma after first-line immunochemotherapy. Blood. 2015;126:333\u2013333.","journal-title":"Blood"},{"key":"1018_CR121","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1182\/blood-2017-04-779736","volume":"130","author":"CW Eskelund","year":"2017","unstructured":"Eskelund CW, et al. TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy. Blood. 2017;130:1903\u201310.","journal-title":"Blood"},{"key":"1018_CR122","doi-asserted-by":"publisher","first-page":"3247","DOI":"10.1182\/blood-2014-01-546150","volume":"123","author":"S Stilgenbauer","year":"2014","unstructured":"Stilgenbauer S, et al. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood. 2014;123:3247\u201354.","journal-title":"Blood"},{"key":"1018_CR123","doi-asserted-by":"publisher","first-page":"2827","DOI":"10.1182\/blood-2019-132275","volume":"134","author":"K Chau","year":"2019","unstructured":"Chau K, et al. Outcomes of 210 patients with follicular and marginal zone lymphomas treated with 4 Gy of radiation therapy. Blood. 2019;134:2827.","journal-title":"Blood"},{"key":"1018_CR124","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.ijrobp.2012.12.024","volume":"86","author":"AL Russo","year":"2013","unstructured":"Russo AL, et al. Low-dose involved-field radiation in the treatment of non-hodgkin lymphoma: predictors of response and treatment failure. Int J Radiat Oncol Biol Phys. 2013;86:121\u20137.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1018_CR125","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/S1470-2045(14)70036-1","volume":"15","author":"PJ Hoskin","year":"2014","unstructured":"Hoskin PJ, et al. 4 Gy versus 24 Gy radiotherapy for patients with indolent lymphoma (FORT): a randomised phase 3 non-inferiority trial. Lancet Oncol. 2014;15:457\u201363.","journal-title":"Lancet Oncol"},{"key":"1018_CR126","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1002\/hon.34_2630","volume":"37","author":"P Hoskin","year":"2019","unstructured":"Hoskin P, et al. Long term follow-up of FoRT: a phase 3 multi-center prospective randomized trial of radiation therapy for follicular and marginal zone lymphoma. Hematol Oncol. 2019;37:219\u201320.","journal-title":"Hematol Oncol"},{"key":"1018_CR127","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1080\/10428190701474365","volume":"48","author":"L Brepoels","year":"2007","unstructured":"Brepoels L, et al. Aggressive and indolent non-Hodgkin\u2019s lymphoma: response assessment by Integrated International Workshop Criteria. Leuk Lymphoma. 2007;48:1522\u201330.","journal-title":"Leuk Lymphoma"},{"key":"1018_CR128","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1002\/hon.2563","volume":"37","author":"D Albano","year":"2019","unstructured":"Albano D, et al. Prognostic role of baseline 18 F-FDG PET\/CT parameters in MALT lymphoma. Hematol Oncol. 2019;37:39\u201346.","journal-title":"Hematol Oncol"},{"key":"1018_CR129","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.ejca.2019.12.006","volume":"126","author":"CL Batlevi","year":"2020","unstructured":"Batlevi CL, et al. Positron-emission tomography\u2013based staging reduces the prognostic impact of early disease progression in patients with follicular lymphoma. Eur J Cancer. 2020b;126:78\u201390.","journal-title":"Eur J Cancer"},{"key":"1018_CR130","doi-asserted-by":"publisher","first-page":"e17","DOI":"10.1016\/S2352-3026(14)70008-0","volume":"1","author":"J Trotman","year":"2014","unstructured":"Trotman J, et al. Prognostic value of PET-CT after fi rst-line therapy in patients with follicular lymphoma: A pooled analysis of central scan review in three multicentre studies. Lancet Haematol. 2014;1:e17\u201327.","journal-title":"Lancet Haematol"},{"key":"1018_CR131","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1016\/S1470-2045(18)30618-1","volume":"19","author":"J Trotman","year":"2018","unstructured":"Trotman J, et al. Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial. Lancet Oncol. 2018;19:1530\u201342.","journal-title":"Lancet Oncol"},{"key":"1018_CR132","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1182\/blood-2017-03-735639","volume":"130","author":"F Scherer","year":"2017","unstructured":"Scherer F, Kurtz DM, Diehn M, Alizadeh AA. High-throughput sequencing for noninvasive disease detection in hematologic malignancies. Blood. 2017;130:440\u201352.","journal-title":"Blood"},{"key":"1018_CR133","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/s41571-019-0187-3","volume":"16","author":"K Pantel","year":"2019","unstructured":"Pantel K, Alix-Panabi\u00e8res C. Liquid biopsy and minimal residual disease\u2014latest advances and implications for cure. Nat Rev Clin Oncol. 2019;16:409\u201324.","journal-title":"Nat Rev Clin Oncol"},{"key":"1018_CR134","doi-asserted-by":"publisher","first-page":"3679","DOI":"10.1182\/blood-2015-03-635169","volume":"125","author":"DM Kurtz","year":"2015","unstructured":"Kurtz DM, et al. Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing. Blood. 2015;125:3679\u201387.","journal-title":"Blood"},{"key":"1018_CR135","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/S1470-2045(15)70106-3","volume":"16","author":"M Roschewski","year":"2015","unstructured":"Roschewski M, et al. Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study. Lancet Oncol. 2015;16:541\u20139.","journal-title":"Lancet Oncol"},{"key":"1018_CR136","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1182\/blood-2017-11-812073","volume":"131","author":"V Spina","year":"2018","unstructured":"Spina V, et al. Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma. Blood. 2018;131:2413\u201325.","journal-title":"Blood"},{"key":"1018_CR137","doi-asserted-by":"publisher","first-page":"8765","DOI":"10.18632\/oncotarget.14448","volume":"8","author":"C Sarkozy","year":"2017","unstructured":"Sarkozy C, et al. The prognostic value of clonal heterogeneity and quantitative assessment of plasma circulating clonal IG-VDJ sequences at diagnosis in patients with follicular lymphoma. Oncotarget. 2017;8:8765\u201374.","journal-title":"Oncotarget"},{"key":"1018_CR138","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1038\/leu.2012.72","volume":"26","author":"C Royo","year":"2012","unstructured":"Royo C, et al. Non-nodal type of mantle cell lymphoma is a specific biological and clinical subgroup of the disease. Leukemia. 2012;26:1895\u20138.","journal-title":"Leukemia"},{"key":"1018_CR139","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1034\/j.1600-0609.2002.00551.x","volume":"68","author":"MK Angelopoulou","year":"2002","unstructured":"Angelopoulou MK, et al. The splenic form of mantle cell lymphoma. Eur J Haematol. 2002;68:12\u201321.","journal-title":"Eur J Haematol"},{"key":"1018_CR140","first-page":"104","volume":"36","author":"GA Pangalis","year":"1999","unstructured":"Pangalis GA, Angelopoulou MK, Vassilakopoulos TP, Siakantaris MP, Kittas C. B-chronic lymphocytic leukemia, small lymphocytic lymphoma, and lymphoplasmacytic lymphoma, including Waldenstr\u00f6m\u2019s macroglobulinemia: a clinical, morphologic, and biologic spectrum of similar disorders. Semin Hematol. 1999;36:104\u201314.","journal-title":"Semin Hematol"},{"key":"1018_CR141","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.beha.2017.02.001","volume":"30","author":"M Armand","year":"2017","unstructured":"Armand M, Besson C, Hermine O, Davi F. Hepatitis C virus\u2014associated marginal zone lymphoma. Best Pract Res Clin Haematol. 2017;30:41\u20139.","journal-title":"Best Pract Res Clin Haematol"},{"key":"1018_CR142","doi-asserted-by":"publisher","first-page":"e498","DOI":"10.1038\/bcj.2016.102","volume":"6","author":"B Fetica","year":"2016","unstructured":"Fetica B, et al. High prevalence of viral hepatitis in a series of splenic marginal zone lymphomas from Romania. Blood Cancer J. 2016;6:e498.","journal-title":"Blood Cancer J"},{"key":"1018_CR143","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1634\/theoncologist.2012-0251","volume":"18","author":"C Kalpadakis","year":"2013","unstructured":"Kalpadakis C, et al. Treatment of splenic marginal zone lymphoma with rituximab monotherapy: progress report and comparison with splenectomy. Oncologist. 2013;18:190\u20137.","journal-title":"Oncologist"},{"key":"1018_CR144","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1182\/blood-2018-02-833608","volume":"132","author":"C Kalpadakis","year":"2018","unstructured":"Kalpadakis C, et al. Rituximab monotherapy in splenic marginal zone lymphoma: prolonged responses and potential benefit from maintenance. Blood. 2018;132:666\u201370.","journal-title":"Blood"},{"key":"1018_CR145","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1002\/cncr.21931","volume":"107","author":"AM Tsimberidou","year":"2006","unstructured":"Tsimberidou AM, et al. Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone. Cancer. 2006;107:125\u201335.","journal-title":"Cancer"},{"key":"1018_CR146","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1111\/bjh.15641","volume":"183","author":"E Iannitto","year":"2018","unstructured":"Iannitto E, et al. Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA\/IELSG36 study. Br J Haematol. 2018;183:755\u201365.","journal-title":"Br J Haematol"},{"key":"1018_CR147","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1080\/136518201753335746","volume":"3","author":"EM Targarona","year":"2001","unstructured":"Targarona EM, Cerd\u00e1n G, Gracia E, Rodr\u00edguez M, Trias M. Results of laparoscopic splenectomy for treatment of malignant conditions. HPB (Oxford). 2001;3:251\u20135.","journal-title":"HPB (Oxford)"},{"key":"1018_CR148","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1097\/00000658-199807000-00006","volume":"228","author":"EM Targarona","year":"1998","unstructured":"Targarona EM, et al. Splenomegaly should not be considered a contraindication for laparoscopic splenectomy. Ann Surg. 1998;228:35\u20139.","journal-title":"Ann Surg"},{"key":"1018_CR149","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1080\/16078454.2019.1591570","volume":"24","author":"J Fallah","year":"2019","unstructured":"Fallah J, Olszewski AJ. Diagnostic and therapeutic splenectomy for splenic lymphomas: analysis of the National Cancer Data Base. Hematology. 2019;24:378\u201386.","journal-title":"Hematology"},{"key":"1018_CR150","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1053\/jinf.2001.0904","volume":"43","author":"N Bisharat","year":"2001","unstructured":"Bisharat N, Omari H, Lavi I, Raz R. Risk of infection and death among post-splenectomy patients. J Infect. 2001;43:182\u20136.","journal-title":"J Infect"},{"key":"1018_CR151","doi-asserted-by":"publisher","first-page":"276.e1","DOI":"10.1016\/j.amjmed.2005.07.044","volume":"119","author":"MH Kyaw","year":"2006","unstructured":"Kyaw MH, et al. Evaluation of severe infection and survival after splenectomy. Am J Med. 2006;119:276.e1-276.e7.","journal-title":"Am J Med"},{"key":"1018_CR152","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1001\/jamasurg.2014.285","volume":"149","author":"N Bagrodia","year":"2014","unstructured":"Bagrodia N, et al. Morbidity and mortality following elective splenectomy for benign and malignant hematologic conditions analysis of the american college of surgeons national surgical quality improvement program data. JAMA Surg. 2014;149:1022\u20139.","journal-title":"JAMA Surg"},{"key":"1018_CR153","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ctrv.2016.11.016","volume":"53","author":"NG Zaorsky","year":"2017","unstructured":"Zaorsky NG, et al. Splenic irradiation for splenomegaly: a systematic review. Cancer Treat Rev. 2017;53:47\u201352.","journal-title":"Cancer Treat Rev"},{"key":"1018_CR154","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.radonc.2015.07.036","volume":"116","author":"AK Trip","year":"2015","unstructured":"Trip AK, et al. Radiation-induced dose-dependent changes of the spleen following postoperative chemoradiotherapy for gastric cancer. Radiother Oncol. 2015;116:239\u201344.","journal-title":"Radiother Oncol"},{"key":"1018_CR155","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1046\/j.1365-2141.1998.1161f.x","volume":"103","author":"A El Weshi","year":"1998","unstructured":"El Weshi A, et al. Low and medium dose spleen radiation therapy are able to induce long-term responses in splenic lymphoma with villous lymphocytes. Br J Haematol. 1998;103:1212\u20133.","journal-title":"Br J Haematol"},{"key":"1018_CR156","doi-asserted-by":"publisher","first-page":"2656","DOI":"10.1200\/JCO.1995.13.10.2656","volume":"13","author":"AC Aisenberg","year":"1995","unstructured":"Aisenberg AC. Coherent view of non-Hodgkin\u2019s lymphoma. J Clin Oncol. 1995;13:2656\u201375.","journal-title":"J Clin Oncol"},{"key":"1018_CR157","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1136\/gutjnl-2011-300495","volume":"61","author":"S Nakamura","year":"2012","unstructured":"Nakamura S, et al. Long-term clinical outcome of gastric MALT lymphoma after eradication of Helicobacter pylori: a multicentre cohort follow-up study of 420 patients in Japan. Gut. 2012;61:507\u201313.","journal-title":"Gut"},{"key":"1018_CR158","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1093\/jrr\/rrw044","volume":"58","author":"Y Ohkubo","year":"2017","unstructured":"Ohkubo Y, et al. Radiotherapy for localized gastric mucosa-associated lymphoid tissue lymphoma: long-term outcomes over 10 years. J Radiat Res. 2017;58:537.","journal-title":"J Radiat Res"},{"key":"1018_CR159","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.cgh.2009.07.017","volume":"8","author":"A Zullo","year":"2010","unstructured":"Zullo A, et al. Effects of helicobacter pylori eradication on early stage gastric mucosa-associated lymphoid tissue lymphoma. Clin Gastroenterol Hepatol. 2010;8:105\u201310.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1018_CR160","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S0140-6736(00)03571-6","volume":"357","author":"H Liu","year":"2001","unstructured":"Liu H, et al. Resistance of t(11;18) positive gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication therapy. Lancet. 2001;357:39\u201340.","journal-title":"Lancet"},{"key":"1018_CR161","doi-asserted-by":"publisher","first-page":"940","DOI":"10.3109\/10428194.2012.729832","volume":"54","author":"M L\u00e9vy","year":"2013","unstructured":"L\u00e9vy M, et al. Rituximab and chlorambucil versus rituximab alone in gastric mucosa-associated lymphoid tissue lymphoma according to t(11;18) status: a monocentric non-randomized observational study. Leuk Lymphoma. 2013;54:940\u20134.","journal-title":"Leuk Lymphoma"},{"key":"1018_CR162","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1002\/path.1715","volume":"205","author":"H Ye","year":"2005","unstructured":"Ye H, et al. MALT lymphoma with t(14;18)(q32;q21)\/IGH-MALT1 is characterized by strong cytoplasmic MALT1 and BCL10 expression. J Pathol. 2005;205:293\u2013301.","journal-title":"J Pathol"},{"key":"1018_CR163","doi-asserted-by":"publisher","first-page":"3861","DOI":"10.1200\/JCO.2001.19.18.3861","volume":"19","author":"P Koch","year":"2001","unstructured":"Koch P, et al. Primary gastrointestinal non-Hodgkin\u2019s lymphoma: I. Anatomic and histologic distribution, clinical features, and survival data of 371 patients registered in the german multicenter study GIT NHL 01\/92. J Clin Oncol. 2001;19:3861\u201373.","journal-title":"J Clin Oncol"},{"key":"1018_CR164","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1080\/10428190600709226","volume":"47","author":"G Papaxoinis","year":"2006","unstructured":"Papaxoinis G, et al. Primary gastrointestinal non-Hodgkin\u2019s lymphoma: a clinicopathologic study of 128 cases in Greece. A Hellenic Cooperative Oncology Group study (HeCOG). Leuk Lymphoma. 2006;47:2140\u20136.","journal-title":"Leuk Lymphoma"},{"key":"1018_CR165","doi-asserted-by":"publisher","first-page":"542","DOI":"10.5858\/arpa.2016-0519-RS","volume":"142","author":"E Marks","year":"2018","unstructured":"Marks E, Shi Y. Duodenal-type follicular lymphoma a clinicopathologic review. Arch Pathol Lab Med. 2018;142:542\u20137.","journal-title":"Arch Pathol Lab Med"},{"key":"1018_CR166","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1002\/1097-0142(19870501)59:9<1670::AID-CNCR2820590925>3.0.CO;2-D","volume":"59","author":"P Salem","year":"1987","unstructured":"Salem P, et al. Primary small intestinal lymphoma in adults. A comparative study of IPSID versus non-IPSID in the middle east. Cancer. 1987;59:1670\u20136.","journal-title":"Cancer"},{"key":"1018_CR167","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1111\/j.1365-2559.1990.tb01157.x","volume":"16","author":"G Li","year":"1990","unstructured":"Li G, Hansmann M-L, Zwingers T, Lennert K. Primary lymphomas of the lung: morphological, immunohistochemical and clinical features. Histopathology. 1990;16:519\u201331.","journal-title":"Histopathology"},{"key":"1018_CR168","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/sj.bjc.6603981","volume":"97","author":"E Chanudet","year":"2007","unstructured":"Chanudet E, et al. Chlamydiae and Mycoplasma infections in pulmonary MALT lymphoma. Br J Cancer. 2007;97:949\u201351.","journal-title":"Br J Cancer"},{"key":"1018_CR169","doi-asserted-by":"publisher","first-page":"2826","DOI":"10.1182\/blood-2019-123257","volume":"134","author":"Y Leyfman","year":"2019","unstructured":"Leyfman Y, et al. Expectant management of extranodal marginal zone lymphoma of bronchial-associated lymphoid tissue (BALT). Blood. 2019;134:2826\u20132826.","journal-title":"Blood"},{"key":"1018_CR170","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1093\/annonc\/mdf175","volume":"13","author":"A Hollender","year":"2002","unstructured":"Hollender A, et al. Central nervous system involvement following diagnosis of non-Hodgkin\u2019s lymphoma: a risk model. Ann Oncol Off J Eur Soc Med Oncol. 2002;13:1099\u2013107.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"1018_CR171","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.3324\/haematol.2015.133744","volume":"100","author":"L Simon","year":"2015","unstructured":"Simon L, et al. Bing-Neel syndrome, a rare complication of waldenstr\u00f6m macroglobulinemia: analysis of 44 cases and review of the literature. A study on behalf of the French Innovative Leukemia Organization (FILO). Haematologica. 2015;100:1587\u201394.","journal-title":"Haematologica"},{"key":"1018_CR172","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1111\/bjh.13883","volume":"172","author":"JJ Castillo","year":"2016","unstructured":"Castillo JJ, et al. Central nervous system involvement by Waldenstr\u00f6m macroglobulinaemia (Bing-Neel syndrome): a multi-institutional retrospective study. Br J Haematol. 2016;172:709\u201315.","journal-title":"Br J Haematol"},{"key":"1018_CR173","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1111\/bjh.16167","volume":"187","author":"JJ Castillo","year":"2019","unstructured":"Castillo JJ, Treon SP. How we manage Bing-Neel syndrome. Br J Haematol. 2019;187:277\u201385.","journal-title":"Br J Haematol"},{"key":"1018_CR174","doi-asserted-by":"publisher","first-page":"E17","DOI":"10.1002\/ajh.24279","volume":"91","author":"A Cabannes-Hamy","year":"2016","unstructured":"Cabannes-Hamy A, et al. Efficacy of ibrutinib in the treatment of Bing-Neel syndrome. Am J Hematol. 2016;91:E17\u20139.","journal-title":"Am J Hematol"},{"key":"1018_CR175","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1182\/blood-2015-05-647834","volume":"126","author":"S Bernard","year":"2015","unstructured":"Bernard S, et al. Activity of ibrutinib in mantle cell lymphoma patients with central nervous system relapse. Blood. 2015;126:1695\u20138.","journal-title":"Blood"},{"key":"1018_CR176","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1080\/10428194.2016.1218006","volume":"58","author":"MI de la Fuente","year":"2017","unstructured":"de la Fuente MI, et al. Marginal zone dural lymphoma: the Memorial Sloan Kettering Cancer Center and University of Miami experiences. Leuk Lymphoma. 2017;58:882\u20138.","journal-title":"Leuk Lymphoma"},{"key":"1018_CR177","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1097\/PAS.0b013e3181f72835","volume":"34","author":"JT Edinger","year":"2010","unstructured":"Edinger JT, Kant JA, Swerdlow SH. Cutaneous marginal zone lymphomas have distinctive features and include 2 subsets. Am J Surg Pathol. 2010;34:1830\u201341.","journal-title":"Am J Surg Pathol"},{"key":"1018_CR178","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.5858\/arpa.2018-0215-RA","volume":"142","author":"SL Skala","year":"2018","unstructured":"Skala SL, Hristov B, Hristov AC. Primary cutaneous follicle center lymphoma. Arch Pathol Lab Med. 2018;142:1313\u201321.","journal-title":"Arch Pathol Lab Med"},{"key":"1018_CR179","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.14289","author":"A Travaglino","year":"2020","unstructured":"Travaglino A, et al. Borrelia burgdorferi in primary cutaneous lymphomas: a systematic review and meta-analysis. JDDG J German Soc Dermatol. 2020. https:\/\/doi.org\/10.1111\/ddg.14289.","journal-title":"JDDG J German Soc Dermatol"},{"key":"1018_CR180","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1097\/00000478-200009000-00012","volume":"24","author":"JR Goodlad","year":"2000","unstructured":"Goodlad JR, et al. Primary cutaneous B-cell lymphoma and Borrelia burgdorferi infection in patients from the highlands of Scotland. Am J Surg Pathol. 2000;24:1279\u201385.","journal-title":"Am J Surg Pathol"},{"key":"1018_CR181","doi-asserted-by":"publisher","first-page":"343.e1","DOI":"10.1016\/j.jaad.2013.06.011","volume":"69","author":"AL Su\u00e1rez","year":"2013","unstructured":"Su\u00e1rez AL, et al. Primary cutaneous B-cell lymphomas: Part II. Therapy and future directions. J Am Acad Dermatol. 2013;69:343.e1-343.e11.","journal-title":"J Am Acad Dermatol"},{"key":"1018_CR182","first-page":"220","volume":"85","author":"F Holm","year":"2020","unstructured":"Holm F, et al. Ocular adnexal lymphoma in Denmark: a nationwide study of 387 cases from 1980 to 2017. Br J Ophthalmol. 2020;85:220.","journal-title":"Br J Ophthalmol"},{"key":"1018_CR183","doi-asserted-by":"publisher","first-page":"4041","DOI":"10.21873\/anticanres.14400","volume":"40","author":"S Rehn","year":"2020","unstructured":"Rehn S, et al. Radiotherapy dose and volume de-escalation in ocular adnexal lymphoma. Anticancer Res. 2020;40:4041\u20136.","journal-title":"Anticancer Res"},{"key":"1018_CR184","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1093\/jnci\/djh102","volume":"96","author":"AJM Ferreri","year":"2004","unstructured":"Ferreri AJM, et al. Evidence for an association between Chlamydia psittaci and ocular adnexal lymphomas. J Natl Cancer Inst. 2004;96:586\u201394.","journal-title":"J Natl Cancer Inst"},{"key":"1018_CR185","doi-asserted-by":"publisher","first-page":"5067","DOI":"10.1200\/JCO.2005.07.083","volume":"23","author":"AJM Ferreri","year":"2005","unstructured":"Ferreri AJM, et al. Regression of ocular adnexal lymphoma after Chlamydia psittaci-eradicating antibiotic therapy. J Clin Oncol. 2005;23:5067\u201373.","journal-title":"J Clin Oncol"},{"key":"1018_CR186","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","volume":"33","author":"C Casulo","year":"2015","unstructured":"Casulo C, et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study. J Clin Oncol. 2015;33:2516\u201322.","journal-title":"J Clin Oncol"},{"key":"1018_CR187","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.3324\/haematol.2018.209015","volume":"104","author":"JF Seymour","year":"2019","unstructured":"Seymour JF, et al. Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression. Haematologica. 2019;104:1202\u20138.","journal-title":"Haematologica"},{"key":"1018_CR188","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1002\/ajh.24492","volume":"91","author":"MJ Maurer","year":"2016","unstructured":"Maurer MJ, et al. Early event status informs subsequent outcome in newly diagnosed follicular lymphoma. Am J Hematol. 2016;91:1096\u2013101.","journal-title":"Am J Hematol"},{"key":"1018_CR189","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1182\/blood.2019000258","volume":"134","author":"CL Freeman","year":"2019","unstructured":"Freeman CL, et al. Early progression after bendamustine-rituximab is associated with high risk of transformation in advanced stage follicular lymphoma. Blood. 2019;134:761\u20134.","journal-title":"Blood"},{"key":"1018_CR190","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1182\/blood.2019001088","volume":"134","author":"S Luminari","year":"2019","unstructured":"Luminari S, et al. Early progression as a predictor of survival in marginal zone lymphomas: an analysis from the FIL-NF10 study. Blood. 2019;134:798\u2013801.","journal-title":"Blood"},{"key":"1018_CR191","doi-asserted-by":"publisher","first-page":"4416","DOI":"10.1182\/blood-2003-10-3411","volume":"103","author":"M Ghielmini","year":"2004","unstructured":"Ghielmini M, et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly\u2009\u00d7\u20094 schedule. Blood. 2004;103:4416\u201323.","journal-title":"Blood"},{"key":"1018_CR192","doi-asserted-by":"publisher","first-page":"3467","DOI":"10.1200\/JCO.2014.59.2139","volume":"33","author":"LH Sehn","year":"2015","unstructured":"Sehn LH, et al. Randomized phase II trial comparing obinutuzumab (GA101) with rituximab in patients with relapsed CD20+ indolent B-Cell non-hodgkin lymphoma: final analysis of the GAUSS study. J Clin Oncol. 2015;33:3467\u201374.","journal-title":"J Clin Oncol"},{"key":"1018_CR193","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S1470-2045(15)00447-7","volume":"17","author":"M Rummel","year":"2016","unstructured":"Rummel M, et al. Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial. Lancet Oncol. 2016;17:57\u201366.","journal-title":"Lancet Oncol"},{"key":"1018_CR194","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s11899-019-00540-w","volume":"14","author":"G von Keudell","year":"2019","unstructured":"von Keudell G, Moskowitz AJ. The role of PI3K inhibition in lymphoid malignancies. Curr Hematol Malig Rep. 2019;14:405\u201313.","journal-title":"Curr Hematol Malig Rep"},{"key":"1018_CR195","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1200\/JCO.18.00915","volume":"37","author":"IW Flinn","year":"2019","unstructured":"Flinn IW, et al. DYNAMO: a Phase II study of duvelisib (IPI-145) in patients with refractory indolent non-hodgkin lymphoma. J Clin Oncol. 2019a;37:912\u201322.","journal-title":"J Clin Oncol"},{"key":"1018_CR196","doi-asserted-by":"publisher","first-page":"3898","DOI":"10.1200\/JCO.2017.75.4648","volume":"35","author":"M Dreyling","year":"2017","unstructured":"Dreyling M, et al. Phosphatidylinositol 3-kinase inhibition by Copanlisib in relapsed or refractory indolent lymphoma. J Clin Oncol. 2017;35:3898\u2013905.","journal-title":"J Clin Oncol"},{"key":"1018_CR197","doi-asserted-by":"publisher","first-page":"3406","DOI":"10.1182\/blood-2013-11-538546","volume":"123","author":"IW Flinn","year":"2014","unstructured":"Flinn IW, et al. Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-\u03b4, as therapy for previously treated indolent non-Hodgkin lymphoma. Blood. 2014b;123:3406\u201313.","journal-title":"Blood"},{"key":"1018_CR198","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1182\/blood-2016-03-707133","volume":"128","author":"BL Lampson","year":"2016","unstructured":"Lampson BL, et al. Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. Blood. 2016;128:195\u2013203.","journal-title":"Blood"},{"key":"1018_CR199","doi-asserted-by":"publisher","first-page":"e18030","DOI":"10.1200\/jco.2015.33.15_suppl.e18030","volume":"33","author":"S Coutre","year":"2015","unstructured":"Coutre S, et al. Safety of idelalisib in B-cell malignancies: Integrated analysis of eight clinical trials. J Clin Oncol. 2015;33:e18030\u2013e18030.","journal-title":"J Clin Oncol"},{"key":"1018_CR200","doi-asserted-by":"publisher","first-page":"2686","DOI":"10.1182\/blood-2015-03-630947","volume":"126","author":"SM O\u2019Brien","year":"2015","unstructured":"O\u2019Brien SM, et al. A phase 2 study of idelalisib plus rituximab in treatment-na\u00efve older patients with chronic lymphocytic leukemia. Blood. 2015;126:2686\u201394.","journal-title":"Blood"},{"key":"1018_CR201","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/S1470-2045(18)30082-2","volume":"19","author":"HA Burris","year":"2018","unstructured":"Burris HA, et al. Umbralisib, a novel PI3K\u03b4 and casein kinase-1\u03b5 inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study. Lancet Oncol. 2018;19:486\u201396.","journal-title":"Lancet Oncol"},{"key":"1018_CR202","first-page":"293663","volume":"2020","author":"J Pagel","year":"2020","unstructured":"Pagel J, et al. (2020) The PI3K\u0394 inhibitor ME-401 is well-tolerated on intermittent\u2026 EHA library. Pagel J. 2020;2020:293663.","journal-title":"Pagel J"},{"key":"1018_CR203","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1182\/blood-2018-08-867499","volume":"133","author":"A Forero-Torres","year":"2019","unstructured":"Forero-Torres A, et al. Parsaclisib, a potent and highly selective PI3Kd inhibitor, in patients with relapsed or refractory B-cell malignancies. Blood. 2019;133:1742\u201352.","journal-title":"Blood"},{"key":"1018_CR204","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1182\/blood-2016-10-747345","volume":"129","author":"A Noy","year":"2017","unstructured":"Noy A, et al. Targeting Bruton tyrosine kinase with ibrutinib in relapsed\/refractory marginal zone lymphoma. Blood. 2017;129:2224\u201332.","journal-title":"Blood"},{"key":"1018_CR205","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/leu.2012.257","volume":"27","author":"N Gachard","year":"2013","unstructured":"Gachard N, et al. IGHV gene features and MYD88 L265P mutation separate the three marginal zone lymphoma entities and Waldenstr\u00f6m macroglobulinemia\/lymphoplasmacytic lymphomas. Leukemia. 2013;27:183\u201399.","journal-title":"Leukemia"},{"key":"1018_CR206","doi-asserted-by":"publisher","first-page":"5773","DOI":"10.1182\/bloodadvances.2020003121","volume":"4","author":"A Noy","year":"2020","unstructured":"Noy A, et al. Durable ibrutinib responses in relapsed\/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis. Blood Adv. 2020;4:5773\u201384.","journal-title":"Blood Adv"},{"key":"1018_CR207","doi-asserted-by":"publisher","first-page":"38180","DOI":"10.18632\/oncotarget.9500","volume":"7","author":"C Wu","year":"2016","unstructured":"Wu C, et al. Genetic heterogeneity in primary and relapsed mantle cell lymphomas: impact of recurrent CARD11 mutations. Oncotarget. 2016;7:38180\u201390.","journal-title":"Oncotarget"},{"key":"1018_CR208","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1182\/blood-2017-09-804641","volume":"131","author":"NL Bartlett","year":"2018","unstructured":"Bartlett NL, et al. Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial. Blood. 2018;131:182\u201390.","journal-title":"Blood"},{"key":"1018_CR209","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","volume":"35","author":"MS Davids","year":"2017","unstructured":"Davids MS, et al. Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-hodgkin lymphoma. J Clin Oncol. 2017;35:826\u201333.","journal-title":"J Clin Oncol"},{"key":"1018_CR210","doi-asserted-by":"publisher","first-page":"e39","DOI":"10.1016\/j.clml.2019.09.060","volume":"19","author":"J Castillo","year":"2019","unstructured":"Castillo J, et al. Multicenter prospective phase II study of venetoclax in patients with previously treated Waldenstrom macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2019;19:e39\u201340.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1018_CR211","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","volume":"378","author":"JF Seymour","year":"2018","unstructured":"Seymour JF, et al. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2018;378:1107\u201320.","journal-title":"N Engl J Med"},{"key":"1018_CR212","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1182\/blood-2017-08-737361","volume":"131","author":"MR Green","year":"2018","unstructured":"Green MR. Chromatin modifying gene mutations in follicular lymphoma. Blood. 2018;131:595\u2013604.","journal-title":"Blood"},{"key":"1018_CR213","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1182\/blood-2019-128096","volume":"134","author":"F Morschhauser","year":"2019","unstructured":"Morschhauser F, et al. Phase 2 multicenter study of tazemetostat, an EZH2 inhibitor, in patients with relapsed or refractory follicular lymphoma. Blood. 2019a;134:123\u2013123.","journal-title":"Blood"},{"key":"1018_CR214","first-page":"2721","volume":"114","author":"D Dornan","year":"2009","unstructured":"Dornan D, et al. Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma. Blood. 2009;114:2721\u20139.","journal-title":"Blood"},{"key":"1018_CR215","doi-asserted-by":"publisher","first-page":"7507","DOI":"10.1200\/JCO.2018.36.15_suppl.7507","volume":"36","author":"LH Sehn","year":"2018","unstructured":"Sehn LH, et al. Randomized phase 2 trial of polatuzumab vedotin (pola) with bendamustine and rituximab (BR) in relapsed\/refractory (r\/r) FL and DLBCL. J Clin Oncol. 2018;36:7507\u20137507.","journal-title":"J Clin Oncol"},{"key":"1018_CR216","doi-asserted-by":"publisher","first-page":"e254","DOI":"10.1016\/S2352-3026(19)30026-2","volume":"6","author":"F Morschhauser","year":"2019","unstructured":"Morschhauser F, et al. Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS). Lancet Haematol. 2019b;6:e254\u201365.","journal-title":"Lancet Haematol"},{"key":"1018_CR217","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1182\/blood-2019-123742","volume":"134","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, et al. Mosunetuzumab induces complete remissions in poor prognosis non-hodgkin lymphoma patients, including those who are resistant to or relapsing after chimeric antigen receptor T-cell (CAR-T) therapies, and is active in treatment through multiple lines. Blood. 2019;134:6.","journal-title":"Blood"},{"key":"1018_CR218","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1002\/hon.57_2629","volume":"37","author":"R Advani","year":"2019","unstructured":"Advani R, et al. The first-in-class anti-CD47 antibody HU5F9-G4\u2009+\u2009rituximab induces durable responses in relapsed\/refractory DLBCL and indolent lymphoma: interim phase 1B\/2 results. Hematol Oncol. 2019;37:89\u201390.","journal-title":"Hematol Oncol"},{"key":"1018_CR219","first-page":"684","volume":"22","author":"C Emmanouilides","year":"2007","unstructured":"Emmanouilides C, et al. Safety and efficacy of yttrium-90 ibritumomab tiuxetan in older patients with non-Hodgkin\u2019s lymphoma. Cancer Biother Radiopharm. 2007;22:684\u201391.","journal-title":"Cancer Biother Radiopharm"},{"key":"1018_CR220","doi-asserted-by":"publisher","first-page":"229","DOI":"10.7326\/M19-2936","volume":"172","author":"GB McDonald","year":"2020","unstructured":"McDonald GB, et al. Survival, nonrelapse mortality, and relapse-related mortality after allogeneic hematopoietic cell transplantation: comparing 2003\u20132007 versus 2013\u20132017 cohorts. Ann Intern Med. 2020;172:229\u201339.","journal-title":"Ann Intern Med"},{"key":"1018_CR221","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1016\/j.bbmt.2018.03.022","volume":"24","author":"V Jurinovic","year":"2018","unstructured":"Jurinovic V, et al. Autologous stem cell transplantation for patients with early progression of follicular lymphoma: a follow-up study of 2 randomized trials from the german low grade lymphoma study group. Biol Blood Marrow Transplant. 2018;24:1172\u20139.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1018_CR222","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1002\/cncr.31374","volume":"124","author":"SM Smith","year":"2018","unstructured":"Smith SM, et al. Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure. Cancer. 2018;124:2541\u201351.","journal-title":"Cancer"},{"key":"1018_CR223","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/j.bbmt.2017.12.771","volume":"24","author":"C Casulo","year":"2018","unstructured":"Casulo C, et al. Autologous transplantation in follicular lymphoma with early therapy failure: a national lymphocare study and center for international blood and marrow transplant research analysis. Biol Blood Marrow Transplant. 2018;24:1163\u201371.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1018_CR224","doi-asserted-by":"publisher","first-page":"4004","DOI":"10.1182\/blood-2007-10-116749","volume":"111","author":"M Ladetto","year":"2008","unstructured":"Ladetto M, et al. Prospective, multicenter randomized GITMO\/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall surviva. Blood. 2008;111:4004\u201318.","journal-title":"Blood"},{"key":"1018_CR225","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1182\/blood-2008-05-160200","volume":"113","author":"E Gyan","year":"2009","unstructured":"Gyan E, et al. High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 year. Blood. 2009;113:995\u20131001.","journal-title":"Blood"},{"key":"1018_CR226","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1016\/j.bbmt.2014.08.019","volume":"20","author":"PB Dahi","year":"2014","unstructured":"Dahi PB, et al. Favorable outcomes in elderly patients undergoing high-dose therapy and autologous stem cell transplantation for non-Hodgkin lymphoma. Biol Blood Marrow Transplant. 2014;20:2004\u20139.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1018_CR227","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bbmt.2015.07.032","volume":"21","author":"NS Majhail","year":"2015","unstructured":"Majhail NS, et al. Indications for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American society for blood and marrow transplantation. Biol Blood Marrow Transplant. 2015;21:1\u20137.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1018_CR228","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1200\/JOP.2017.026336","volume":"13","author":"M Hamadani","year":"2017","unstructured":"Hamadani M, Horowitz MM. Allogeneic transplantation for follicular lymphoma: does one size fit all? J Oncol Pract. 2017;13:798\u2013806.","journal-title":"J Oncol Pract"},{"key":"1018_CR229","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1002\/cncr.31264","volume":"124","author":"A Sureda","year":"2018","unstructured":"Sureda A, et al. Allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma: a combined analysis on behalf of the Lymphoma Working Party of the EBMT and the Lymphoma Committee of the CIBMTR. Cancer. 2018;124:1733\u201342.","journal-title":"Cancer"},{"key":"1018_CR230","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1182\/bloodadvances.2018018531","volume":"2","author":"NN Shah","year":"2018","unstructured":"Shah NN, et al. Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: a CIBMTR analysis. Blood Adv. 2018;2:933\u201340.","journal-title":"Blood Adv"},{"key":"1018_CR231","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1182\/blood-2015-09-671834","volume":"127","author":"AS Kanate","year":"2016","unstructured":"Kanate AS, et al. Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors. Blood. 2016;127:938\u201347.","journal-title":"Blood"},{"key":"1018_CR232","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.1200\/JCO.2015.66.3476","volume":"34","author":"N Ghosh","year":"2016","unstructured":"Ghosh N, et al. Reduced-intensity transplantation for lymphomas using haploidentical related donors versus HLA-matched sibling donors: a center for international blood and marrow transplant research analysis. J Clin Oncol. 2016;34:3141\u20139.","journal-title":"J Clin Oncol"},{"key":"1018_CR233","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.bbmt.2013.11.029","volume":"20","author":"CS Sauter","year":"2014","unstructured":"Sauter CS, et al. A Phase II study of a nonmyeloablative allogeneic stem cell transplant with peritransplant rituximab in patients with BCell lymphoid malignancies: favorably durable event-free survival in chemosensitive patients. Biol Blood Marrow Transplant. 2014;20:354\u201360.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1018_CR234","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377:2531\u201344.","journal-title":"N Engl J Med"},{"key":"1018_CR235","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","volume":"377","author":"SJ Schuster","year":"2017","unstructured":"Schuster SJ, et al. Chimeric antigen receptor T Cells in refractory B-Cell lymphomas. N Engl J Med. 2017;377:2545\u201354.","journal-title":"N Engl J Med"},{"key":"1018_CR236","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1182\/blood.2019000905","volume":"134","author":"AV Hirayama","year":"2019","unstructured":"Hirayama AV, et al. High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy. Blood. 2019;134:636\u201340.","journal-title":"Blood"},{"key":"1018_CR237","doi-asserted-by":"publisher","first-page":"8008","DOI":"10.1200\/JCO.2020.38.15_suppl.8008","volume":"38","author":"CA Jacobson","year":"2020","unstructured":"Jacobson CA, et al. Interim analysis of ZUMA-5: a phase II study of axicabtagene ciloleucel (axi-cel) in patients (pts) with relapsed\/refractory indolent non-Hodgkin lymphoma (R\/R iNHL). J Clin Oncol. 2020;38:8008.","journal-title":"J Clin Oncol"},{"key":"1018_CR238","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25:625\u201338.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1018_CR239","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/nrclinonc.2017.128","volume":"15","author":"JN Brudno","year":"2017","unstructured":"Brudno JN, Kochenderfer JN. Chimeric antigen receptor T-cell therapies for lymphoma. Nat Rev Clin Oncol. 2017;15:31\u201346.","journal-title":"Nat Rev Clin Oncol"},{"key":"1018_CR240","doi-asserted-by":"publisher","first-page":"e160","DOI":"10.1097\/HS9.0000000000000160","volume":"1","author":"K Herfarth","year":"2018","unstructured":"Herfarth K, et al. Rituximab with involved field irradiation for early-stage nodal follicular lymphoma. HemaSphere. 2018;1:e160.","journal-title":"HemaSphere"},{"key":"1018_CR241","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1200\/JCO.18.00605","volume":"37","author":"IW Flinn","year":"2019","unstructured":"Flinn IW, et al. First-line treatment of patients with indolent non-hodgkin lymphoma or mantle-cell lymphoma with bendamustine plus rituximab versus R-CHOP or R-CVP: results of the BRIGHT 5-year follow-up study. J Clin Oncol. 2019b;37:984\u201391.","journal-title":"J Clin Oncol"},{"key":"1018_CR242","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/S1470-2045(16)30097-3","volume":"17","author":"LH Sehn","year":"2016","unstructured":"Sehn LH, et al. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. Lancet Oncol. 2016;17:1081\u201393.","journal-title":"Lancet Oncol"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-020-01018-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-020-01018-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-020-01018-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T02:05:45Z","timestamp":1680055545000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-020-01018-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,6]]},"references-count":242,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["1018"],"URL":"https:\/\/doi.org\/10.1186\/s13045-020-01018-6","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,6]]},"assertion":[{"value":"26 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5"}}